Abstract:Yun Seob Jung, 1 Byung Hak Jin, 2 Ju Eun Choi, 2 Min Soo Park, 2 Young-Woo Kim, 3 Hyung Won Kang, 4 Sunyoung Cho, 5 Choon Ok Kim 2 1 Department of Pharmacology, Yonsei University College of Medicine, Seoul, Korea; 2 Department of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul, Korea; 3 School of Korean Medicine, Dongguk University, Gyeongju, Korea; 4 College of Korean Medicine, Wonkwang University, Iksan, Korea; 5 IntegroMediLab Co., Ltd, Seoul, Korea Correspondence: Choon Ok Kim, Department of Clinical Pharmacology, Severance Hospital, Yonsei University Health System, Seoul, Korea, Tel +82-2-2228-0455, Fax +82-2-2227-7890, Email Purpose: Herbal medicines are occasionally used in combination with conventional antidepressants to mitigate various depression-associated symptoms. However, there is limited information on herb–antidepressant interactions. In this study, we investigated the pharmacokinetic (PK) effects of four herbal medicines (Gami-soyosan, Banhasasim-tang, Ojeok-san, and Bojungikgi-tang) on escitalopram, a commonly used antidepressant. Patients and Methods: In this open-label, fixed-sequence, three-period, crossover study, 18 participants were enrolled and divided into two groups. Each group received a 10 mg oral dose of escitalopram in period 1. Participants took escitalopram once daily and their assigned herbal medicines thrice a day for 7 d in periods 2 (group 1: Gami-soyosan, group 2: Ojeok-san) and 3 (group 1: Banhasasim-tang; group 2: Bojungikgi-tang). The primary endpoints were C max,ss and AUC tau,ss of escitalopram. C max,ss and AUC tau,ss in period 1 were obtained using nonparametric superposition from single-dose data. The PK endpoints were classified according to the CYP2C19 phenotype. Results: Of 18 participants, 16 completed the study. Systemic exposure to escitalopram resulted in a minor increase in the presence of each herbal medicine. The geometric mean ratios (GMRs, combination with herbal medicines/escitalopram monotherapy) and their 90% confidence intervals (CIs) for C max,ss and AUC tau,ss were as follows: Gamisoyosan– 1.1454 (0.9201, 1.4258) and 1.0749 (0.8084, 1.4291), Banhasasim-tang– 1.0470 (0.7779, 1.4092) and 1.0465 (0.7035, 1.5568), Ojeok-san– 1.1204 (0.8744, 1.4357) and 1.1267 (0.8466, 1.4996), and Bojungikgi-tang– 1.1264 (0.8594, 1.4762) and 1.1400 (0.8515, 1.5261), respectively. Furthermore, no significant differences in the GMRs of C max,ss and AUC tau,ss were observed across different CYP2C19 phenotypes in any of the groups. Conclusion: The co-administration of escitalopram with Gami-soyosan, Banhasasim-tang, Ojeok-san, or Bojungikgi-tang did not exert significant PK effects on escitalopram. These findings provide valuable insights into the safe use of herbal medicines along with escitalopram. Keywords: CYP2C19 phenotype, herb–drug interaction, antidepressant, geometric mean ratio Depressive disorder is a psychiatric disease characterized by mood, cognition, and motor function symptoms, ultimately affecting an individual's working and social abilities. 1,2 The World Health Organization has emphasized the importance of diagnosing and treating depressive disorders owing to their emergence as a global public health concern. 3 It is estimated that depression will become the leading cause of global disease burden by 2030. 4 Failure to provide appropriate treatment for depressive symptoms can result in their persistence, leading to a decline in the patient's quality of life and difficulties in social functioning. Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly used drugs for treating depressive disorders. SSRIs include fluoxetine, escitalopram, paroxetine, citalopram, and others. 5 Serotonin is a monoamine neurotransmitter that reduces anxiety, depression, and aggression. Under normal circumstances, serotonin is released in the brain and is reabsorbed by presynaptic neurons at the synapse, effectively disappearing. 6 However, SSRIs block the reuptake process of serotonin by presynaptic neurons, allowing serotonin to remain in the brain for an extended period, accounting for their psychiatric effects. 5,6 Among various SSRIs, escitalopram is frequently prescribed for depressive disorders. Escitalopram is an S-enantiomer of the racemate citalopram, another SSRI that was developed earlier. Escitalopram shows dose linearity within the range of 10–30 mg and has a half-life of approximately 27–32 h, achieving a steady-state within 7 d of daily dosing. 7</sup -Abstract Truncated-

Pharmacokinetics of escitalopram in Chinese healthy volunteers after single and multiple oral administration

Pharmacokinetics of escitalopram in Chinese healthy volunteers after oral administration of different doses

Pharmacokinetics of Escitalopram in Healthy Volunteers

Pharmacokinetics and bioequivalence study of escitalopram oxalate formulations after single-dose administration in healthy Chinese male volunteers

CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population

Comparison of Bioavailability and Bioequivalence of Generic and Brand Name Formulations of Escitalopram Oxalate Tablets in Healthy Chinese Population Under Fasting and Fed Conditions

The clinical pharmacokinetics of escitalopram

Pharmacokinetic study of eszopiclone in healthy Chinese volunteers

Escitalopram population pharmacokinetics and remedial strategies based on CYP2C19 phenotype

Comparative bioavailability of two escitalopram formulations in healthy human volunteers

Pharmacokinetics of fluoxetine hydrochloride enteric-coated tablets after a single oral administration in healthy Chinese volunteers

[Pharmacokinetics and Relative Bioavailability of Ziprasidone Tablets in Chinese Healthy Volunteers].

Pharmacokinetics of Dapoxetine Hydrochloride in Chinese Healthy Male Volunteers

Assessment of Pharmacokinetic Effects of Herbal Medicines on Escitalopram

Efficacy and Safety of Escitalopram in Treatment of Severe Depression in Chinese Population.

Pharmacokinetics and safety of tadalafil in Chinese male healthy subjects after a single dose oral administration

Escitalopram Vs Citalopram: a Parallel Controlled Study for Depression

Efficacy of Escitalopram Monotherapy in the Treatment of Major Depressive Disorder

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.

The perception and pharmacokinetics of a 20-mg dose of escitalopram orodispersible tablets in a relative bioavailability study in healthy men

Pharmacokinetics and Tolerability of Extended-Release Quetiapine Fumarate in Han Chinese Patients with Schizophrenia